Rheinfelden - Tillotts Pharma AG ('Tillotts') celebrates its 10th anniversary as part of the Japanese Zeria Group and marks the occasion during the company's Board Meeting in Rheinfelden, Switzerland, with a traditional tea ceremony in the company's Japanese-inspired room 'Little Japan.'
The celebration already started this September when the CEO Thomas A. Toth von Kisker, together with Tillotts' top management, visited Japan. On this occasion, Mr. Sachiaki Ibe, Chairman and CEO of Zeria Pharmaceutical Co. Ltd., handed over a Japanese artwork depicting Mount Fuji to Thomas A. Toth as a symbol of Zeria's appreciation of Tillotts' strong performance since the acquisition.
During the past 10 years, Tillotts has generated double-digit growth and successfully expanded its portfolio as part of its Vision 2020 strategy. The portfolio now includes two first-line products indicated respectively for the treatment of mild to moderate ulcerative colitis (UC) and Crohn's disease, together known as Inflammatory Bowel Diseases (IBD). Tillotts' success and progress can largely be attributed to the outstanding performance of our dedicated employees, who are committed to providing innovative treatment solutions to IBD patients. This commitment has also led to the development of the first 1600 mg mesalazine tablet for the treatment of mild to moderate UC.
Mr. Sachiaki Ibe states, 'Tillotts' performance over the past 10 years has been outstanding, and I dearly appreciate the great performance and contribution to the Zeria Group. Our collaboration with Tillotts was further consolidated with the establishment of Zeria Group Innovation, which I am confident will have a positive impact on the future development of Tillotts and Zeria. I again would like to thank Tillotts for the great successes achieved and hope for further growth of both Zeria and Tillotts through our joint efforts.'
'I cannot think of a better parent company than Zeria. They have trusted us completely to make the decisions needed to further strengthen Tillotts' position as an important player in the field of gastroenterology. Our success has allowed us to expand our network of affiliates in Europe, and we are confident that we will continue to establish our presence in and outside of Europe very soon. Zeria has supported us with the needed resources when we identified opportunities to expand our portfolio and pipeline. We are all thankful for their commitment and dedication, which has enabled us to provide better treatment opportunities for our patients now and in the future,' Thomas A. Toth says.
Contact:
Julie Delin Fosdal
Tel: +41 61 935 2761
Email: Julie Fosdal@tillotts.com
About Tillotts
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD as well as in-licensed products, in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
All trademarks used or mentioned here are protected by law. The rights to Asacol, including the rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.
About Zeria
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries.
ZERIA PHARMACEUTICAL CO., LTD. 
